HomeAI · summaries
Storia in 3 fonti
Mounjaro sales double this year as obesity drug boom prevails, says maker
The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
- ·
zerohedge.com
"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand
"At the same time, Lilly is building for the future. With our next-generation weight-loss medicine..."
